目的:探讨白蛋白紫杉醇治疗既往接受过三线或三线以上治疗的晚期非小细胞肺癌患者的临床疗效和不良反应。方法:回顾性分析2010年8月至2012年6月确诊为晚期非小细胞肺癌的16例患者,接受白蛋白紫杉醇化疗的疗效以及不良反应。白蛋白紫杉醇...目的:探讨白蛋白紫杉醇治疗既往接受过三线或三线以上治疗的晚期非小细胞肺癌患者的临床疗效和不良反应。方法:回顾性分析2010年8月至2012年6月确诊为晚期非小细胞肺癌的16例患者,接受白蛋白紫杉醇化疗的疗效以及不良反应。白蛋白紫杉醇130 mg/m^2(d1,d8,d15)单药静脉化疗,每4周为1个疗程,每2个周期评价疗效。结果:16例患者中,男性13例,女性3例;中位年龄57(40～75)岁;腺癌8例,鳞癌4例,其他4例;吸烟10例,不吸烟6例。全组患者中,部分缓解(partial response,PR)3例(18.75%),疾病稳定(stable disease,SD)5例(32.25%),疾病进展(progressive disease,PD)8例(50.00%)。客观缓解率(objectiveresponse rate,ORR)18.75%,疾病控制率(disease control rate,DCR)50.00%。中位疾病进展时间(median time to progression,MTTP)为2.15个月。主要不良反应是脱发(37.50%)、中性粒细胞减少(31.25%)和末梢神经毒性(12.50%)。结论:白蛋白紫杉醇在经过多线抗肿瘤治疗后的晚期非小细胞肺癌治疗中仍显示出一定疗效,不良反应可以接受,值得进一步进行大样本研究加以验证。展开更多
Objective： To study the expression of extracellular matrix （ECM） proteins including Collagen Ⅳ （Co Ⅳ）, Fibronectin, Laminin in human non-small cell lung cancer （NSCLC） specimens and the relationship between E...Objective： To study the expression of extracellular matrix （ECM） proteins including Collagen Ⅳ （Co Ⅳ）, Fibronectin, Laminin in human non-small cell lung cancer （NSCLC） specimens and the relationship between ECM and cell adhesion, proliferation, apoptosis and drug sensitivity in NSCLC cell line. And to investigate the role of phosphatidylinositol 3-kinase （PI3-K） in signal transduction of Co Ⅳ in NSCLC. Methods： The expression of ECM proteins was detected by using immunohistochemical staining （Envision＇s）. Adherent cells were stained with 1% methylene blue. Cell proliferation and cytotoxic effects were monitored by MTT assay. Cell apoptosis was analyzed by FITC-Annexin V/PI double staining variables flow cytometry （FCM）. Results： The expression rate of Co Ⅳ （93%） was the highest compared to others in NSCLC stroma. After treated with Co Ⅳ, the adhesion of H1299 cells was increased and the cytotoxicity of cis-platinum （DDP） against H1299 cells was decreased compared to the control （P〈0.05）. After treated with Co Ⅳ both survival and proliferation rates were higher and apoptosis rate was lower than without Co Ⅳ （P〈0.05）. PI3-K inhibitor LY294002 decreased both survival and proliferation rates （82.7%±2.0% and 75.2%±6.8%, respectively）, even on Co Ⅳ-coated surface （92.2%±2.8% and 84.6%±9.2%, respectively）. And it also helped DDP increase apoptosis. Conclusion： ECM remodeling existed in NSCLC. Co Ⅳ protected NSCLC cells from DDP-induced apoptosis and weakened the cytotoxicity of DDP. PI3-K pathway might be the crucial mechanism of apoptosis impairment and drug resistance.展开更多
为会员国和其他相关机构提供公共卫生服务的循征医学指南是世界卫生组织（World Health Organization，WHO）的核心职责之一。WHO关于耐多药（multidrug--resistanttuberculosis，MDR-TB）或利福平耐药结核病（rifampiein-resistanttube...为会员国和其他相关机构提供公共卫生服务的循征医学指南是世界卫生组织（World Health Organization，WHO）的核心职责之一。WHO关于耐多药（multidrug--resistanttuberculosis，MDR-TB）或利福平耐药结核病（rifampiein-resistanttuberculosis，RR-TB）治疗的最新循证医学指南于2016年10月发布.展开更多
文摘目的:探讨白蛋白紫杉醇治疗既往接受过三线或三线以上治疗的晚期非小细胞肺癌患者的临床疗效和不良反应。方法:回顾性分析2010年8月至2012年6月确诊为晚期非小细胞肺癌的16例患者,接受白蛋白紫杉醇化疗的疗效以及不良反应。白蛋白紫杉醇130 mg/m^2(d1,d8,d15)单药静脉化疗,每4周为1个疗程,每2个周期评价疗效。结果:16例患者中,男性13例,女性3例;中位年龄57(40～75)岁;腺癌8例,鳞癌4例,其他4例;吸烟10例,不吸烟6例。全组患者中,部分缓解(partial response,PR)3例(18.75%),疾病稳定(stable disease,SD)5例(32.25%),疾病进展(progressive disease,PD)8例(50.00%)。客观缓解率(objectiveresponse rate,ORR)18.75%,疾病控制率(disease control rate,DCR)50.00%。中位疾病进展时间(median time to progression,MTTP)为2.15个月。主要不良反应是脱发(37.50%)、中性粒细胞减少(31.25%)和末梢神经毒性(12.50%)。结论:白蛋白紫杉醇在经过多线抗肿瘤治疗后的晚期非小细胞肺癌治疗中仍显示出一定疗效,不良反应可以接受,值得进一步进行大样本研究加以验证。
基金This project was supported by the Science Foundation of Shanghai Municipal Commission of Science and Technology (034119953).
文摘Objective： To study the expression of extracellular matrix （ECM） proteins including Collagen Ⅳ （Co Ⅳ）, Fibronectin, Laminin in human non-small cell lung cancer （NSCLC） specimens and the relationship between ECM and cell adhesion, proliferation, apoptosis and drug sensitivity in NSCLC cell line. And to investigate the role of phosphatidylinositol 3-kinase （PI3-K） in signal transduction of Co Ⅳ in NSCLC. Methods： The expression of ECM proteins was detected by using immunohistochemical staining （Envision＇s）. Adherent cells were stained with 1% methylene blue. Cell proliferation and cytotoxic effects were monitored by MTT assay. Cell apoptosis was analyzed by FITC-Annexin V/PI double staining variables flow cytometry （FCM）. Results： The expression rate of Co Ⅳ （93%） was the highest compared to others in NSCLC stroma. After treated with Co Ⅳ, the adhesion of H1299 cells was increased and the cytotoxicity of cis-platinum （DDP） against H1299 cells was decreased compared to the control （P〈0.05）. After treated with Co Ⅳ both survival and proliferation rates were higher and apoptosis rate was lower than without Co Ⅳ （P〈0.05）. PI3-K inhibitor LY294002 decreased both survival and proliferation rates （82.7%±2.0% and 75.2%±6.8%, respectively）, even on Co Ⅳ-coated surface （92.2%±2.8% and 84.6%±9.2%, respectively）. And it also helped DDP increase apoptosis. Conclusion： ECM remodeling existed in NSCLC. Co Ⅳ protected NSCLC cells from DDP-induced apoptosis and weakened the cytotoxicity of DDP. PI3-K pathway might be the crucial mechanism of apoptosis impairment and drug resistance.
文摘为会员国和其他相关机构提供公共卫生服务的循征医学指南是世界卫生组织（World Health Organization，WHO）的核心职责之一。WHO关于耐多药（multidrug--resistanttuberculosis，MDR-TB）或利福平耐药结核病（rifampiein-resistanttuberculosis，RR-TB）治疗的最新循证医学指南于2016年10月发布.
